Pharmaceutical Executive
Migraine specialist abandons one problematic drug and maintains its position by filing an NDA the following week.
Pharmaceutical Executive-08-16-2005
Pharmaceutical Executive
Only a year after the National Human Genome Research Institute called for improving sequencing technology, two new methods were announced in the same week. What will the goal of a $1000 human genome mean for medicine and disease research?
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
